Register
Journal Updates
eMediNexus Coverage from: 
Canagliflozin shown to be renoprotective in type 2 diabetes patients with CKD
eMediNexus,  16 April 2019
remove_red_eye 527 Views
#Diabetes and Endocrinology #Nephrology #Pathology and Lab Medicine #Pharmacist

0 Read Comments                

In patients with type 2 diabetes and stage 2 or 3 kidney disease, the risk of kidney failure and cardiovascular events was lower with once daily oral canagliflozin 100 mg than with placebo group at a median follow-up of 2.62 years, according to the results of the phase III CREDENCE trial (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) trial presented at the 2019 World Congress of Nephrology in Melbourne, Australia, and simultaneously published April 14, 2019 in the New England Journal o
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!